Table 2.
CTC EP |
CTC EMT |
CTC Any |
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Protein Expression | Negative N (%) | Positive N (%) | P Value | Negative N (%) | Positive N (%) | P Value | Negative N (%) | Positive N (%) | P Value | |
APC | Negative | 77 (46.7) | 9 (52.9) | .622 | 76 (48.1) | 8 (27.6) | .041 | 71 (48.6) | 15 (34.9) | .112 |
Positive | 88 (53.3) | 8 (47.1) | 82 (51.9) | 21 (72.4) | 75 (51.4) | 28 (65.1) | ||||
ADAM23 | Negative | 40 (24.2) | 6 (35.3) | .318 | 39 (24.8) | 8 (26.7) | .833 | 34 (23.4) | 13 (29.5) | .412 |
Positive | 125 (75.8) | 11 (64.7) | 118 (75.2) | 22 (73.3) | 111 (76.6) | 31 (70.5) | ||||
CXCL12 | Negative | 39 (23.5) | 3 (17.6) | .585 | 40 (25.2) | 3 (10.3) | .081 | 40 (27.2) | 5 (11.6) | .035 |
Positive | 127 (76.5) | 14 (82.4) | 119 (74.8) | 26 (89.7) | 107 (72.8) | 38 (88.4) | ||||
E-cadherin | Negative | 59 (39.9) | 11 (64.7) | .050 | 61 (42.4) | 11 (42.3) | .996 | 53 (40.2) | 21 (52.5) | .167 |
Positive | 89 (60.1) | 6 (35.3) | 83 (57.6) | 15 (57.7) | 79 (59.8) | 19 (47.5) | ||||
RASSF1* | Negative | 20 (31.7) | 3 (27.3) | .767 | 23 (32.4) | 1 (12.5) | .246 | 20 (31.3) | 4 (23.5) | .535 |
Positive | 43 (68.3) | 8 (72.7) | 48 (67.6) | 7 (87.5) | 44 (68.8) | 13 (76.5) | ||||
SYK | Negative | 63 (38.0) | 5 (29.4) | .488 | 58 (36.7) | 12 (40.0) | .732 | 54 (37.0) | 16 (36.4) | .940 |
Positive | 103 (62.0) | 12 (70.6) | 100 (63.3) | 18 (60.0) | 92 (63.0) | 28 (63.6) | ||||
TIMP3 | Negative | 79 (48.2) | 12 (75.0) | .040 | 80 (51.3) | 13 (44.8) | .523 | 71 (49.0) | 23 (54.8) | .508 |
Positive | 85 (51.8) | 4 (25.0) | 76 (48.7) | 16 (55.2) | 74 (51.0) | 19 (45.2) | ||||
BRMS1 | Negative | 11 (6.7) | 2 (11.8) | .447 | 14 (9.0) | 2 (6.9) | .715 | 12 (8.3) | 4 (9.3) | .842 |
Positive | 152 (93.3) | 15 (88.2) | 142 (91.0) | 27 (93.1) | 132 (91.7) | 39 (90.7) | ||||
SOCS1 | Negative | 5 (3.0) | 6 (35.3) | < .001 | 11 (7.0) | 1 (3.4) | .478 | 5 (3.4) | 7 (16.3) | .002 |
Positive | 160 (97.0) | 11 (64.7) | 147 (93.0) | 28 (96.6) | 141 (96.6) | 36 (83.7) |
Number of samples analyzed in the study was n = 203; only successfully analyzed samples were included in the table.
For RASSF1, protein analyses were performed on 61 samples only because of the lack of material (tumor tissue).